BMS is a common condition characterized by chronic oral mucosal pain condition 
and primarily affects elderly women. Although clonazepam therapy has been widely 
used due to its efficacy, it is not always effective because of the complexity 
of BMS pathogenesis. In this study, we have investigated outcome predictors of 
clonazepam therapy in patients with BMS. One hundred patients with BMS (7 men 
and 93 women, mean age 58.5 ± 10.8 years) were instructed to take 0.5mg of 
clonazepam once or twice daily for 4 weeks. The patients were sub-grouped 
according to psychological status, salivary flow rate, presence of psychiatric 
medications, symptom area and duration, symptom severity, presence of oral 
parafunctions, and accompanying oral complaints. The changes in symptoms were 
analyzed and compared between the sub-groups. Subjects with T-scores ≤50 for 
each psychological symptom dimension, a greater degree of initial symptoms 
(visual analog scale (VAS)≥5), and accompanying oral complaints, such as 
xerostomia and taste disturbance, displayed greater decreases in symptoms 
compared with their counterparts. In conclusion, psychological status, initial 
symptom severity, and the presence of xerostomia and/or taste disturbance can 
serve as outcome predictors of clonazepam therapy for patients with BMS.